Home Search
RVVTF - search results
If you're not happy with the results, please do another search
Revive Therapeutics (RVVTF) $0.02, Explores the Use of Bucillamine for Long COVID.
Bucillamine is one of the most amazing drugs (in our opinion), which was repurposed from its original use as an anti-inflammatory for use with...
Revive Therapeutics (RVVTF) Advancing MDMA Thermal Patch.
Two News Reports Related to Revives Upcoming Microneedle Patch Technology
While we are still laser focused on Revive having a successful meeting with the FDA...
Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that the amended protocol is still under...
Revive Therapeutics (RVVTF) Annual Shareholder Meeting.
ANNUAL SHAREHOLDER MEETING
https://vimeo.com/752050831
CORPORATE PRESENTATION | AUGUST 2022
NEWS ARCHIVE
Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company...
Revive Therapeutics (RVVTF) Enters the Danger Zone.
What Danger You Ask?
Danger #1, the FDA doesn't like the data, and you own the stock.
Danger #2, the FDA does like the data, and...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
As we stated earlier, Revive Therapeutics (RVVTF)...
Revive Therapeutics (RVVTF) Regulatory Update Archive.
April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as the rate...
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
NEWS ARCHIVE INTRO
“These medicines have a sweet spot. If the day you get diagnosed with COVID you...
Latest article
We’re Up 360% in Six Weeks. Replimune (REPL).
That's a Gain of $604 Million, and That Ain't Bad!
Six brokerage firms downgraded Replimune (REPL), around the same time we added it to...
GeoVax (GOVX) Conference Call and Transcript.
Excellent Presentation. You Can Listen for 40 Minutes, or Read it in About Ten, Halleluiah.
Guess what we'll choose to do?
We have no...
Sekur Private Data (SWISF) Awarded Distribution Agreement With Elyon International.
Top Ranked Defense, Government and Enterprise Contractor
Trying to Break Over $0.06.
We are still sitting on the edge of our seat waiting for contract news,...
